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INTRODUCTION
Cigarette smoking is accepted as a major risk
factor for ischemic heart disease (IHD) as well as
hypertension and hyperlipidemia (1). Certain compo-
nents of cigarette smoke, such as nicotine and carbon
monoxide, have been reporterd to be responsible
for the development of IHD by increasing plasma
catecholamine levels and producing hypoxia (2). On
the other hand, cigarette smoking alters plasma
lipoprotein levels (3-5) and increases the susceptibil-
ity of low density lipoprotein (LDL) to oxidation (6).
However, the exact mechanism responsible for the
harmful effect of smoking on IHD is not fully under-
stood (7).
High density lipoprotein-cholesterol (HDL-C) is
known to be an important protective factor for IHD.
Several epidemiological studies have indicated that
low serum levels of HDL-C are associated with an
increased risk of IHD (8-10). Reverse cholesterol
transport is also an antiatherogenic process in which
excess cholesterol is transported from peripheral
tissues back to the liver or to other peripheral tissues
that in need cholesterol. The excess cholersterol is
taken by HDL and esterified by lecithin : cholesterol
acyltransferase (LCAT, EC 2. 3. 1. 43) and cholesteryl
esters are transfered from HDL towards very-low
and low-density lipoproteins (VLDL and LDL) by
cholesterol ester transfer protein (CETP) (11).
Conflicting data on the influence of smoking on
LCAT activity have been published In this respect
we investigated the effects of smoking on the levels
of plasma lipids, lipoproteins, apolipoproteins and
LCAT activity in fasting blood from healthy smokers
and nonsmokers, matched for age and body mass
index (BMI).
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MATERIALS AND METHODS
Twenty-seven cigarette smokers and thirty-one
non-smokers were investigated. All subjects were
men. The smokers smoked at least 10 cigarettes per
day (mean, 18 ± 6 cigarettes ; range 10 to 30) for
at least 7 years (mean, 15 ± 6 years, range 7 to 28).
The non-smokers had never smoked in the past.
The ages of the subjects were 29 to 53. Subjects
with hepatic, renal or cardiovascular disease, and
diabetes mellitus were excluded. None of them were
taking any drugs, such as beta-blockers, diuretics
or lipid-lowering agents. Informed consent was ob-
tained from each participant in the study.
Blood was drawn from an antecubital vein into
vacutainer tubes after 10-12 hours of fasting. Blood
was centrifuged at 1500 g for 15 minutes. Sera were
stored at -20℃ and analyzed within 30 days. Serum
triglyceride (TG) level was determined enzymatically
(Biosystems, Spain). Total cholesterol (TC) was
measured with the Lieberman-Burchard method.
Free cholesterol (FC) was determined in serum
and HDL fraction with the Lieberman-Burchard
method after digitonin precipitation (12). HDL-C
was assayed after the precipitation of apolipopro-
tein (apo) B-containing lipoproteins with dextran
sulphate-magnesium chloride (13). LDL-C was deter-
mined according to Friedewald et al (14). Esterified
cholesterol was deduced from the difference be-
tween total and free cholesterol. Apo A-I and apo B
were measured by nephelometry (Sanofi Pasteur,
France). Lipoprotein (a) was analyzed by ELISA
(Chromogenix, Sweden). Serum LCAT activity was
determined as a function of the decrease of free
cholesterol which is esterified during incubation at
37℃, as described by Hitz et al (15).
Results are expressed as mean±SD. The Student’s
t-test was used to compare the smoker and non-
smoker subjects. A p value of <0.05 was considered
to be significant.
RESULTS
The study groups comprised of 27 male smokers
(mean age ± SD, 41.9 ± 6.7 years) and 31 male
non-smokers (41.5 ± 6.9 years). The body mass
indexes were 25.6 ± 2.8 and 26.4 ± 3.5 kg/m2 in
smokers and non-smokers, respectively (Table 1).
There were no significant differences in serum TC,
TG, lipoprotein (a), apo A-I and B, LDL-C and
HDL- and serum-free and- ester cholesterol levels
between smokers and non-smokers. Serum LCAT
activity was lower in smokers than in non-smokers,
although this difference was statistically nonsignifi-
cant (Table 2 and 3).
The smoker and non-smoker subjects were grouped
Table 1. Characteristics of healthy smokers and non-smokers
n
Age, years
Body mass index, kg/m2
Exposure to cigarette smoke*
Smokers
27
41.9±6.7
25.6±2.8
278±160
Nonsmokers
31
41.5±6.9
26.4±3.5
‐
* Brinkmann Index (cigarettes per day for X years)
Table 2. Serum lipid, lipoprotein and apolipoprotein concen-
trations (mg/dL) and LCAT activity (µmol.L-1.h-1) in smokers
and non-smokers*
Analytes Non-smokers Smokers
TC 218±61 231±67
TG 200±136 201±103
HDL-C 48.6±7.2 51.7±9.9
LDL-C 127±47 141±64
TC/HDL-C 4.6±1.6 4.7±1.8
HDL-FC 14.5±7.0 13.0±5.3
HDL-EC 34.8±8.2 38.7±9.8
HDL-EC/HDL-FC 3.2±2.1 3.5±1.7
S. FC 81.5±36.4 84.4±30.6
S. EC 140.5±39.6 147.4±42.0
S. EC/S. FC 2.0±0.9 1.9±0.5
Apo A-I 155±28 149±25
Apo B 143±40 148±42
Lp (a) 36.6±37.7 37.4±40.2
LCAT 82.3±54.9 69.0±48.8
*All values are given as mean±SD
TC : Total cholesterol, TG : Triglyceride, HDL-C : High density
lipoprotein-cholesterol
LDL-C : Low density lipoprotein-cholesterol, HDL-FC : HDL-Free
cholesterol
HDL-EC : HDL-Ester cholesterol, S. FC : Serum free cholesterol,
S. EC : Serum ester cholesterol, Apo-A-I and Apo B : Apolipo-
protein A-I and B, Lp (a) : Lipoprotein (a),
LCAT : Lecithin : cholesterol acyltransferase
(Note : The statistical significance in all the parameters compared
between the two groups were not significant, p>0.05)
Table 3. Serum LCAT activity, based on exposure to cigarette
smoke.
LCAT activity
(µmol.L-1.h-1)
Brinkmann
index<200
n : 12
81.4±50.8
Brinkmann
‐index > 200
n : 15
59.2±45.1
p
>0.05
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into normolipidemics (n : 30) and hyperlipidemics [n :
28, isolated hypercholesterolemia (n : 8) and mixed
hypertriglyceridemia (n : 20)] HDL-C and HDL-esterified
cholesterol were lower in normolipidemic-smokers
than in normolipidemic-nonsmokers (Table 4).
DISCUSSION
Smoking is a significant risk factor for IHD. There
are several studies showing associations between
cigarette smoking and altered serum lipid and lipo-
protein concentrations. These alterations, which are
associated with smoking, are higher serum levels
of TC, TG, VLDL-C, LDL-C and lower serum levels
of HDL-C and Apo A-I. Many of these variables have
been associated with an increased risk of IHD (5).
Several studies have reported that serum HDL-C
level is found to be lower in smokers than in
non-smokers (16-18). However Siekmeier et al . (19)
reported that smoker and non-smoker subjects had
similar HDL-C levels ; this result agrees with our
result. In this study, concentrations of TC, TG,
LDL-C, HDL-C, Lp (a), apo A-I and B did not differ
between smokers and non-smokers.
There are several studies showing lower serum
LCAT concentrations or activities in smokers com-
pared to non-smokers (20, 21). Haffner et al. reported
a negative correlation between smoking and LCAT
mass (21). The positive correlation between LCAT
concentration and TC and LDL-C was also reported
in these studies (20-22). These findings are in ac-
cordance with the suggestion that LCAT plays an
important role in the reverse transport of cholesterol.
In addition to in vivo studies, in vitro studies have
shown that cigarette smoke inhibited LCAT activity
(23). In another study, it was reported that rats given
nicotine had lower LCAT activity (24). However, in
several studies, LCAT activity was found not to be
different in smokers and non-smokers (7, 17, 22,
25). In our study, serum LCAT activity was found
to be 15.8% lower in smokers than in non-smokers,
but this difference was not statistically significant.
The data indicate that cigarette smoking does not
affect lipid, lipoprotein and apolipoprotein levels.
LCAT activity tended to be lower in smokers compared
to non-smokers. So, it may be considered that the
reverse cholesterol transport can be diminished
and cholesterol can accumulate in the peripheral
tissues, more in the smokers than non-smokers.
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